登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C29H53NO5
化学文摘社编号:
分子量:
495.73
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
orlistat
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
InChI
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
InChI key
AHLBNYSZXLDEJQ-FWEHEUNISA-N
Gene Information
human ... LIPF(8513), PNLIP(5406)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Biochem/physiol Actions
奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
溶液不完全澄清，小颗粒可能仍然悬浮。
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 奥利司他
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Juliet M Mancino
Current diabetes reports, 6(5), 389-394 (2006-11-02)
Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in
Robert H Nelson et al.
Expert opinion on pharmacotherapy, 6(14), 2483-2491 (2005-11-02)
Orlistat (tetrahydrolipstatin) is an inhibitor of gastrointestinal lipases, especially pancreatic lipase. It is used as an adjunct to diet and exercise in order to achieve weight loss in obese individuals (body mass index > 30 kg/m2) or in overweight individuals
D N Kiortsis et al.
Diabetes & metabolism, 31(1), 15-22 (2005-04-02)
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1478800-200MG | 04061838737694 |